Aerovate Therapeutics (AVTE) Q3 2024 earnings summary

Executive summary

• Halted development of AV-101 after negative Phase 2b trial results; no plans to resume or develop new candidates.

• Announced a major workforce reduction, terminating about 90% of employees by September 30, 2024.

• Entered into a merger agreement with Jade Biosciences, with closing expected in the first half of 2025.

• Pre-merger stockholders to receive a cash dividend of approximately $65 million, subject to adjustment.

• Jade to raise $300 million in a concurrent investment, with the combined company to be led by Jade's CEO.

Financial highlights

• Net loss of $16.2 million for Q3 2024, compared to $19.6 million in Q3 2023.

• Net loss of $64.2 million for the nine months ended September 30, 2024, up from $55.1 million year-over-year.

• Operating expenses for Q3 2024 were $17.4 million, down from $21.4 million in Q3 2023.

• Cash, cash equivalents, and short-term investments totaled $88.7 million as of September 30, 2024.

• Net cash used in operating activities was $60.1 million for the nine months ended September 30, 2024.

Outlook and guidance

• Existing cash and investments expected to fund operations for at least twelve months from the filing date.

• Future operations highly dependent on successful completion of the merger with Jade.

• No plans to resume AV-101 or initiate new product development; focus is on strategic alternatives.